

CLAIM LISTING

This listing of claims will replace all prior versions and listings of the claims in the application:

1. (currently amended) A method of increasing the immunogenicity of a carbohydrate antigen, the method comprising conjugating the antigen to tetanus toxin Fragment C to yield a conjugated vaccine,

wherein upon administration of the conjugated vaccine to a patient the Fragment C increases the potency of the antigen.
2. (original) The method according to claim 1, wherein the antigen is a capsular polysaccharide from a bacterium.
3. (original) The method according to claim 2, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1, 2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.
4. (original) The method according to claim 1, wherein the antigen is a capsular polysaccharide from a fungus.

5. (original) The method according to claim 4, wherein the fungus is selected from the group consisting *Candida albicans* and *Cryptococcus neoformans*.
6. (currently amended) A method of immunizing a patient against an infection, the method comprising administering to the patient an effective dose of a vaccine comprising an antigen that has been conjugated to Fragment C, wherein said antigen is a capsular polysaccharide.
7. (original) The method according to claim 6, wherein the antigen is a capsular polysaccharide from a bacterium.
8. (original) The method according to claim 7, wherein the bacterium is selected from the group consisting of *Meningococcus* group A, B, C, Y, W135 and X; *Streptococcus* group A, B, and C; *Pneumococcus* types 1, 2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23; *Staphylococcus aureus* types 5 and 8 and *Haemophilus influenzae* type b.
9. (original) The method according to claim 6, wherein the antigen is a capsular polysaccharide from a fungus.
10. (withdrawn) The method according to claim 9, wherein the fungus is selected from the group consisting *Candida albicans* and *Cryptococcus neoformans*.

11. (currently amended) A conjugated vaccine comprising an antigen that has been conjugated to Fragment C, wherein said antigen is a capsular polysaccharide.
12. (original) The conjugated vaccine according to claim 11, wherein the antigen is a capsular polysaccharide from a bacterium.
13. (original) The conjugated vaccine according to claim 12, wherein the bacterium is selected from the group consisting of Meningococcus group A, B, C, Y, W135 and X; Streptococcus group A, B, and C; Pneumococcus types 1, 2, 3, 4, 6A, 6B, 9, 14, 18F, 19F and 23; Staphylococcus aureus types 5 and 8 and Haemophilus influenzae type b.
14. (original) The conjugated vaccine according to claim 11, wherein the antigen is a capsular polysaccharide from a fungus.
15. (original) The method according to claim 14, wherein the fungus is selected from the group consisting Candida albicans and Cryptococcus neoformans.